Yang Kairui
The Stony Brook School, 1 Chapman Pkwy, Stony Brook, NY 11790, USA.
Virus Res. 2025 Jun 21;358:199601. doi: 10.1016/j.virusres.2025.199601.
Emerging pathogens underscore an urgent need for rapidly developed vaccines to minimize mortality and societal disruption. Traditional vaccine development requires time spans of years, making it ill-suited to fast evolving viruses that can overwhelm healthcare systems and economies. In response, plug-and-play vaccine platforms offer a more agile solution. By reusing proven backbones, they reduce the repetitive safety and production steps otherwise required for each new pathogen, thus accelerating both regulatory approval and large-scale manufacturing. In parallel, artificial intelligence and computational tools enable faster antigen and epitope identification, more accurate immune response modeling, and improved vaccine design. These innovations have already shortened timelines and enhanced efficacy.
新出现的病原体凸显了对快速开发疫苗的迫切需求，以尽量减少死亡率和社会混乱。传统疫苗开发需要数年时间，这使其不适用于能压垮医疗系统和经济的快速演变的病毒。作为回应，即插即用疫苗平台提供了一种更灵活的解决方案。通过复用经过验证的主干，它们减少了针对每种新病原体原本所需的重复性安全和生产步骤，从而加快了监管审批和大规模生产的速度。与此同时，人工智能和计算工具能够更快地识别抗原和表位，更准确地模拟免疫反应，并改进疫苗设计。这些创新已经缩短了研发时间并提高了疗效。
